CD34 and acute myeloid leukemia: Recently, work from our own laboratory and others’, has shown that, as with AML, it is possible to isolate malignant populations with phenotypes corresponding to all normal developing B cell precursors including, in high risk disease, those with HSC phenotype CD34+CD19− (Castor et al, 2005; Hotfilder et al, 2005).